Glix 40 Tablet contains Gliclazide 40 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glix 40 is typically prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels. The drug exhibits a selective action on pancreatic receptors, which may result in a lower risk of hypoglycemia compared to other sulfonylureas. It is metabolized hepatically and excreted primarily via the kidneys. Dosage adjustments should be individualized based on patient response and glycemic monitoring. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and minimize complications. Glix 40 should be used under medical supervision, with attention to potential drug interactions and patient-specific factors to ensure safe and effective diabetes management.